| 摘要 |
The invention provides a polypeptide sequence, GHIKSSISFMGM, that disrupts binding of the amino acid sequence peptides of myelin basic protein (MBP) to HLA-DR2 class II MHC molecules and acts as an antagonist in DR2-restricted antigen presentation to human T cell clones. In particular, the invention provides the polypeptide sequence itself and variants, compositions comprising the polypeptide, polynucleotides encoding the polypeptide, and methods for using the polypeptides and polynucleotides for treating autoimmune disorders.
|
